JPS60202822A - 抗ウイルス薬 - Google Patents
抗ウイルス薬Info
- Publication number
- JPS60202822A JPS60202822A JP59059844A JP5984484A JPS60202822A JP S60202822 A JPS60202822 A JP S60202822A JP 59059844 A JP59059844 A JP 59059844A JP 5984484 A JP5984484 A JP 5984484A JP S60202822 A JPS60202822 A JP S60202822A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- antiviral agent
- compound
- infectious diseases
- daily dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003443 antiviral agent Substances 0.000 title claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims description 4
- -1 pyridobenzoxazine compound Chemical class 0.000 abstract description 5
- 208000035473 Communicable disease Diseases 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 4
- 239000002775 capsule Substances 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 4
- 239000007924 injection Substances 0.000 abstract description 4
- 201000007100 Pharyngitis Diseases 0.000 abstract description 2
- 206010035664 Pneumonia Diseases 0.000 abstract description 2
- 206010006451 bronchitis Diseases 0.000 abstract description 2
- 206010023332 keratitis Diseases 0.000 abstract description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 abstract description 2
- 206010039083 rhinitis Diseases 0.000 abstract description 2
- 208000003265 stomatitis Diseases 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 241000712461 unidentified influenza virus Species 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000470 constituent Substances 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 210000004392 genitalia Anatomy 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- QDEJGQKJMKXYLM-UHFFFAOYSA-N 2h-pyrido[2,3-h][1,2]benzoxazine Chemical class C1=CC2=NC=CC=C2C2=C1C=CNO2 QDEJGQKJMKXYLM-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010072210 Genital herpes zoster Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 206010066888 Herpes pharyngitis Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000005130 benzoxazines Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000009837 laryngotracheitis Diseases 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59059844A JPS60202822A (ja) | 1984-03-28 | 1984-03-28 | 抗ウイルス薬 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59059844A JPS60202822A (ja) | 1984-03-28 | 1984-03-28 | 抗ウイルス薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60202822A true JPS60202822A (ja) | 1985-10-14 |
| JPH0347251B2 JPH0347251B2 (enExample) | 1991-07-18 |
Family
ID=13124923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59059844A Granted JPS60202822A (ja) | 1984-03-28 | 1984-03-28 | 抗ウイルス薬 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60202822A (enExample) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990013542A1 (en) * | 1989-04-28 | 1990-11-15 | Daiichi Pharmaceutical Co., Ltd. | Anti-hiv drug |
| US5175160A (en) * | 1988-08-09 | 1992-12-29 | Daiichi Pharmaceutical Co., Ltd. | Antimicrobial agent for animals |
| AU638421B2 (en) * | 1989-04-28 | 1993-07-01 | Daiichi Pharmaceutical Co., Ltd. | An anti-human immunodeficiency virus composition |
| JPH0682976U (ja) * | 1993-05-19 | 1994-11-29 | 西川産業株式会社 | 二重蒲団 |
| WO1998042341A1 (en) * | 1997-03-25 | 1998-10-01 | Sankyo Company, Limited | Anti-fiv agent |
| WO1999033835A1 (en) * | 1997-12-24 | 1999-07-08 | Sankyo Company, Limited | Fused-ring quinolinecarboxylic acid derivatives |
| US9326936B2 (en) | 2008-10-07 | 2016-05-03 | Raptor Pharmaceuticals, Inc. | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| RU2583890C2 (ru) * | 2014-08-19 | 2016-05-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Белгородский государственный аграрный университет имени В.Я. Горина" | Способ лечения гингивитов, пародонтитов и зубного камня у собак |
| US9700564B2 (en) | 2009-09-04 | 2017-07-11 | Horizon Orphan Llc | Use of aerosolized levofloxacin for treating cystic fibrosis |
| US10987357B2 (en) | 2005-05-18 | 2021-04-27 | Horizon Orphan, LLC | Aerosolized fluoroquinolones and uses thereof |
| US11020481B2 (en) | 2008-10-07 | 2021-06-01 | Horizon Orphan Llc | Topical use of levofloxacin for reducing lung inflammation |
-
1984
- 1984-03-28 JP JP59059844A patent/JPS60202822A/ja active Granted
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5175160A (en) * | 1988-08-09 | 1992-12-29 | Daiichi Pharmaceutical Co., Ltd. | Antimicrobial agent for animals |
| WO1990013542A1 (en) * | 1989-04-28 | 1990-11-15 | Daiichi Pharmaceutical Co., Ltd. | Anti-hiv drug |
| AU638421B2 (en) * | 1989-04-28 | 1993-07-01 | Daiichi Pharmaceutical Co., Ltd. | An anti-human immunodeficiency virus composition |
| JPH0682976U (ja) * | 1993-05-19 | 1994-11-29 | 西川産業株式会社 | 二重蒲団 |
| WO1998042341A1 (en) * | 1997-03-25 | 1998-10-01 | Sankyo Company, Limited | Anti-fiv agent |
| WO1999033835A1 (en) * | 1997-12-24 | 1999-07-08 | Sankyo Company, Limited | Fused-ring quinolinecarboxylic acid derivatives |
| US10987357B2 (en) | 2005-05-18 | 2021-04-27 | Horizon Orphan, LLC | Aerosolized fluoroquinolones and uses thereof |
| US10722519B2 (en) | 2008-10-07 | 2020-07-28 | Horizon Orphan Llc | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| US9717738B2 (en) | 2008-10-07 | 2017-08-01 | Horizon Orphan Llc | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| US10149854B2 (en) | 2008-10-07 | 2018-12-11 | Horizon Orphan Llc | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| US9326936B2 (en) | 2008-10-07 | 2016-05-03 | Raptor Pharmaceuticals, Inc. | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| US11020481B2 (en) | 2008-10-07 | 2021-06-01 | Horizon Orphan Llc | Topical use of levofloxacin for reducing lung inflammation |
| US9700564B2 (en) | 2009-09-04 | 2017-07-11 | Horizon Orphan Llc | Use of aerosolized levofloxacin for treating cystic fibrosis |
| US10231975B2 (en) | 2009-09-04 | 2019-03-19 | Horizon Orphan Llc | Use of aerosolized levofloxacin for treating cystic fibrosis |
| US10792289B2 (en) | 2009-09-04 | 2020-10-06 | Horizon Orphan Llc | Use of aerosolized levofloxacin for treating cystic fibrosis |
| RU2583890C2 (ru) * | 2014-08-19 | 2016-05-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Белгородский государственный аграрный университет имени В.Я. Горина" | Способ лечения гингивитов, пародонтитов и зубного камня у собак |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0347251B2 (enExample) | 1991-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4879277A (en) | Antiviral compositions and methods | |
| JPS60202822A (ja) | 抗ウイルス薬 | |
| JPS59130223A (ja) | 相乗作用を示す抗ヘルペス組成物 | |
| CA2109435C (en) | Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals | |
| Taylor et al. | Protection against Japanese encephalitis virus in mice and hamsters by treatment with carboxymethylacridanone, a potent interferon inducer | |
| WO1991002529A2 (en) | Product and method for killing abnormal vertebrate cells | |
| CA1318850C (en) | Pharmaceutical products | |
| ES2105923A1 (es) | Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv). | |
| IL106491A0 (en) | Anti viral preparations | |
| US5840763A (en) | Treatment of a latent infection of herpes viruses | |
| JPS5970615A (ja) | 口唇疱疹治療へのウンデシレン酸の使用 | |
| Steffenhagen et al. | Evaluation of 6-azauridine and S-iododeoxyuridine in the treatment of experimental viral infections | |
| CA1336491C (en) | Antiviral pharmaceutical composition | |
| US20230398090A1 (en) | Method of treating coronavirus infection by administration of ethyl mercury or thiol derivative thereof | |
| JPH0768136B2 (ja) | 抗ウイルス治療 | |
| US4230725A (en) | Antiviral agent | |
| KR0141648B1 (ko) | B형 바이러스(hbv)성 감염의 예방 및 치료용 약학적 제제 | |
| RU1822787C (ru) | Противогриппозное средство | |
| AU690159B2 (en) | Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections | |
| RU2333752C1 (ru) | Противовирусное средство | |
| KR100382707B1 (ko) | 잠재적허피스바이러스감염의치료및예방을위한아미노퓨린항바이러스제의용도 | |
| JPH11501625A (ja) | ヒト・ヘルペスウイルス−８の治療に対するペンシクロビルの使用 | |
| RU2181049C2 (ru) | Использование аминопуриновых противовирусных соединений для лечения и профилактики латентных инфекций, вызванных вирусом герпеса | |
| JPH07188032A (ja) | インフルエンザ治療薬 | |
| Schwartz et al. | Antiviral agents |